By Michele Maatouk
Date: Wednesday 05 Aug 2026
(Sharecast News) - Eli Lilly lifted its full-year guidance on Wednesday as weight-loss jabs Mounjaro and Zepbound drove an increase in second-quarter sales.
| Currency | US Dollars |
| Share Price | $ 1,179.27 |
| Change Today | $ 9.67 |
| % Change | 0.83 % |
| 52 Week High | $1,281.49 |
| 52 Week Low | $799.57 |
| Volume | 1,392,930 |
| Shares Issued | 944.80m |
| Market Cap | $1,114,174m |
| RiskGrade | 179 |
| Strong Buy | 13 |
| Buy | 11 |
| Neutral | 3 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 28 |

| Time | Volume / Share Price |
| 16:00 | 204,476 @ $1,179.27 |
| 15:59 | 40 @ $1,178.70 |
| 15:59 | 72 @ $1,178.70 |
| 15:59 | 104 @ $1,178.70 |
| 15:59 | 40 @ $1,178.70 |
You are here: research